Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

ClinicalTrials.gov ID: NCT00031837

Public ClinicalTrials.gov record NCT00031837. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective Randomized Controlled Multicenter Study of the Effect of Dalteparin on Quality of Life in Unresectable Pancreatic Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Anticoagulants such as dalteparin may help prevent blood clots in patients being treated with gemcitabine for unresectable or metastatic pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without dalteparin in treating patients who have unresectable or metastatic pancreatic cancer.

Study identification

NCT ID: NCT00031837
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Gary Morrow; Other
Enrollment: 400 participants

Conditions and interventions

Conditions

Interventions

Drug · Procedure

Eligibility (public fields only)

Age range: 18 Years to 120 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2002 (Type not available)
Primary completion: Dec 2006 (Actual)
Completion: Dec 2006 (Actual)
Last update posted: Oct 14, 2015

2002 – 2006

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 13

Facility	City	State	ZIP	Site status
MBCCOP - Gulf Coast	Mobile	Alabama	36607	—
CCOP - Colorado Cancer Research Program, Incorporated	Denver	Colorado	80224	—
MBCCOP - University of Illinois at Chicago	Chicago	Illinois	60612-7323	—
CCOP - Central Illinois	Decatur	Illinois	62526	—
CCOP - Kalamazoo	Kalamazoo	Michigan	49007-3731	—
CCOP - Kansas City	Kansas City	Missouri	64131	—
CCOP - Hematology-Oncology Associates of Central New York	East Syracuse	New York	13057	—
University of Rochester Cancer Center CCOP Research Base	Rochester	New York	14642	—
CCOP - Southeast Cancer Control Consortium	Goldsboro	North Carolina	27534-9479	—
CCOP - Columbus	Columbus	Ohio	43215	—
CCOP - Dayton	Dayton	Ohio	45429	—
CCOP - Greenville	Greenville	South Carolina	29615	—
CCOP - Northwest	Tacoma	Washington	98405-0986	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00031837, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 14, 2015 · Synced Oct 25, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00031837 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →